Cartesian Grants New Hire 50,000-Share Option
The option, priced at $6.34 and vesting through 2030, is a routine inducement grant under Nasdaq rules.
Updated on Nov. 3, 2026 in Biotech
Cartesian Therapeutics granted one new employee an option to buy 50,000 shares of common stock at $6.34 per share, the Nasdaq closing price on the grant date. The grant is a routine equity inducement tied to the employee's hiring, not a product or clinical development.
Why it matters
Inducement grants like this are a standard way for clinical-stage biotech companies to recruit staff without drawing on shareholder-approved plans, and the terms show how the company is compensating new hires. The story is a small corporate filing rather than a technology milestone.
The grant is a 10-year option on 50,000 shares, with a 25% cliff at the one-year mark followed by monthly vesting over three years, a standard four-year schedule. The filing discloses the exercise price and vesting terms only; no valuation or dilution percentage is provided.
The players
Cartesian Therapeutics
A Frederick, Maryland-based clinical-stage biotechnology company whose common stock trades on the Nasdaq Global Market.
The details
Cartesian Therapeutics issued the option under its Amended and Restated 2018 Employment Inducement Incentive Award Plan, a plan that lets companies grant equity to new hires outside their general stock plans. Nasdaq Listing Rule 5635(c)(4) permits this kind of grant without a shareholder vote when it is an inducement for someone entering employment. The option's exercise price is set at the stock's closing price on the grant date, so the employee only gains if the share price rises above $6.34.
Timeline
November 2, 2026: option granted to the new employee at $6.34 per share.
November 2, 2027: first 25% of the option vests.
November 2, 2030: option is fully vested.
The Tech Race
The grant is an administrative equity award under the Nasdaq inducement exception and places Cartesian within no competitive technology race. It reflects routine staffing practice for a clinical-stage company listed on the Nasdaq Global Market.
The grant has no direct effect on patients, customers or the public. Its practical relevance is limited to the employee, who will receive shares only if the stock trades above $6.34 and the vesting conditions are met.
The takeaway
Inducement grants are a recurring feature of biotech compensation, so filings like this one are useful for tracking how a company recruits. Readers can watch the company's later Nasdaq disclosures for further hiring or grant activity.
Further reading
For broader context on clinical-stage companies in the Biotech section, see related coverage of the sector.
